Nimotuzumab is a non-intrinsically stimulating anti-EGFR monoclonal antibody that blocks the binding of EGFR to its ligand and exhibits anti-angiogenic, anti-tumor cell proliferative, and pro-apoptotic effects in EGFR-overexpressing tumors [11]. The gene discussed is EGFR; the disease is neoplasm.